## **Core Concept**
The question tests understanding of antiemetic therapy, specifically for chemotherapy-induced nausea and vomiting (CINV). Cisplatin is a highly emetogenic chemotherapeutic agent. Effective management of CINV often involves combination therapy with different classes of antiemetics.

## **Why the Correct Answer is Right**
Ondansetron, a **5-HT3 receptor antagonist**, is highly effective in controlling acute CINV, especially when induced by highly emetogenic chemotherapy like cisplatin. Cisplatin induces the release of serotonin from the small intestine, which then stimulates 5-HT3 receptors in the vagus nerve, triggering the vomiting reflex. By blocking these receptors, ondansetron effectively reduces the incidence of acute nausea and vomiting.

## **Why Each Wrong Option is Incorrect**
- **Option A:** While metoclopramide is an antiemetic, its effectiveness against cisplatin-induced vomiting is lower compared to ondansetron, especially at high doses required for such emetogenic chemotherapy.
- **Option B:** Although dexamethasone is a corticosteroid used in antiemetic protocols for its anti-inflammatory and antiemetic properties, it is not as effective alone in controlling acute cisplatin-induced vomiting as ondansetron.
- **Option D:** Promethazine is a first-generation antihistamine with antiemetic properties but is less effective against chemotherapy-induced nausea and vomiting compared to ondansetron.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that for highly emetogenic chemotherapy like cisplatin, the combination of a **5-HT3 antagonist** (like ondansetron), a **NK1 receptor antagonist** (like aprepitant), and a **corticosteroid** (like dexamethasone) provides the best protection against both acute and delayed CINV.

## **Correct Answer:** . Ondansetron